GGHC
VNDA icon

Gilder Gagnon Howe & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-84,613
Closed -$1.21M – 284
2014
Q4 		$1.21M Buy
84,613
+1,423
+2% +$16.8K 0.02% 198
2014
Q3 		$864K Buy
+83,190
New +$1.09M 0.01% 210
2013
Q4 		– Sell
-11,908
Closed -$130K – 262
2013
Q3 		$130K Buy
11,908
+644
+6% +$6.88K ﹤0.01% 238
2013
Q2 		$91K Buy
+11,264
New +$75.9K ﹤0.01% 247

Other funds holding VNDA

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gilder Gagnon Howe & Co's VNDA Position: Q1 2015 in Review

Gilder Gagnon Howe & Co sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 84,613 shares — an estimated $1.21M sold.

Gilder Gagnon Howe & Co first reported a position in VNDA in Q2 2013 and held it in 4 quarters. The position peaked at $1.21M in Q4 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

  • Gilder Gagnon Howe & Co reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 84,613 Vanda Pharmaceuticals shares in Q1 2015, an estimated $1.21M.
  • Gilder Gagnon Howe & Co first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Vanda Pharmaceuticals position peaked at $1.21M in Q4 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2015, filed 30 Apr 2015.